Literature DB >> 25600150

Regulation of drug transporter expression and function in the placenta.

Frantisek Staud1, Martina Ceckova.   

Abstract

INTRODUCTION: Medication of pregnant women is increasingly common in developed countries. Several placental drug transporters have been shown to transfer their substrates from the trophoblast back to the maternal circulation, thus hindering the transplacental passage of xenobiotics and protecting the fetus. However, the expression and activity of drug transporter proteins in the placenta vary during gestation and are tightly regulated by many factors. In addition, their function can be compromised by pathological conditions and/or drug-drug interactions. AREAS COVERED: This article reviews current knowledge on placental drug transporters, their effects on placental pharmacokinetics and the regulatory mechanisms that control their expression and activity. Transcriptional, genetic and epigenetic mechanisms of placental transporter regulation and the drug-drug interactions that modulate transporter activity are described. Physiological and pathological factors that can affect drug transporter expression and function in the placenta are also discussed. EXPERT OPINION: The expression and activity of drug transporter proteins in the placenta vary during gestation and are tightly regulated by many factors. Subsequently, there is a great variability in the expression and function of placental drug transporters both within human populations (interindividual variability) and also during gestation (intraindividual variability). An understanding of the expression and function of placental drug transporters is essential for efficient and safe therapy during pregnancy. There is clearly a need for further preclinical and clinical studies on placental drug transporters, but such investigations must be carefully designed and the resulting data should be evaluated with great caution. This review highlights several methodological aspects that will have to be considered and addressed in order to shed further light on these important issues.

Entities:  

Keywords:  drug transporter; epigenetics; expression; genetics; gestation; pharmacokinetics; pharmacotherapy; placenta; pregnancy; regulation

Mesh:

Substances:

Year:  2015        PMID: 25600150     DOI: 10.1517/17425255.2015.1005073

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  11 in total

Review 1.  Disruption of small molecule transporter systems by Transporter-Interfering Chemicals (TICs).

Authors:  Sascha C T Nicklisch; Amro Hamdoun
Journal:  FEBS Lett       Date:  2020-12-09       Impact factor: 4.124

Review 2.  Timing in drug absorption and disposition: The past, present, and future of chronopharmacokinetics.

Authors:  Joana Bicker; Gilberto Alves; Amílcar Falcão; Ana Fortuna
Journal:  Br J Pharmacol       Date:  2020-03-20       Impact factor: 8.739

3.  Multiple Drug Transporters Contribute to the Placental Transfer of Emtricitabine.

Authors:  Qingquan Zeng; Mengru Bai; Cui Li; Shuanghui Lu; Zhiyuan Ma; Yunchun Zhao; Hui Zhou; Huidi Jiang; Dongli Sun; Caihong Zheng
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  Glutamate cycling may drive organic anion transport on the basal membrane of human placental syncytiotrophoblast.

Authors:  Emma M Lofthouse; Suzanne Brooks; Jane K Cleal; Mark A Hanson; Kirsten R Poore; Ita M O'Kelly; Rohan M Lewis
Journal:  J Physiol       Date:  2015-09-09       Impact factor: 5.182

5.  Effect of Histone Deacetylase Inhibition on the Expression of Multidrug Resistance-associated Protein 2 in a Human Placental Trophoblast Cell Line.

Authors:  Hong-Yu Duan; Dan Ma; Kai-Yu Zhou; Tao Wang; Yi Zhang; Yi-Fei Li; Jin-Lin Wu; Yi-Min Hua; Chuan Wang
Journal:  Chin Med J (Engl)       Date:  2017-06-05       Impact factor: 2.628

6.  Maternal use of drug substrates of placental transporters and the effect of transporter-mediated drug interactions on the risk of congenital anomalies.

Authors:  Aizati N A Daud; Jorieke E H Bergman; Monika P Oktora; Wilhelmina S Kerstjens-Frederikse; Henk Groen; Jens H Bos; Eelko Hak; Bob Wilffert
Journal:  PLoS One       Date:  2017-03-13       Impact factor: 3.240

7.  HDAC1 was involved in placental breast cancer resistance protein regulation in vitro: A preliminary study.

Authors:  Hongyu Duan; Kaiyu Zhou; Yi Zhang; Peng Yue; Tao Wang; Yifei Li; Dajian Qiu; Yimin Hua; Chuan Wang
Journal:  J Cell Mol Med       Date:  2019-05-22       Impact factor: 5.310

8.  Modulation of Placental Breast Cancer Resistance Protein by HDAC1 in Mice: Implications for Optimization of Pharmacotherapy During Pregnancy.

Authors:  Chuan Wang; Dan Ma; Yimin Hua; Hongyu Duan
Journal:  Reprod Sci       Date:  2021-10-19       Impact factor: 3.060

Review 9.  Chemotherapy against cancer during pregnancy: A systematic review on neonatal outcomes.

Authors:  Susanna Esposito; Rossana Tenconi; Valentina Preti; Elena Groppali; Nicola Principi
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

10.  Placental transporter-mediated drug interactions and offspring congenital anomalies.

Authors:  Maria Ellfolk; Aleksi Tornio; Mikko Niemi; Maarit K Leinonen; Anna-Maria Lahesmaa-Korpinen; Heli Malm
Journal:  Br J Clin Pharmacol       Date:  2020-01-20       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.